Acumen Pharmaceuticals Inc Market Cap ($16.93 Million)
Market Cap & Net Worth: Acumen Pharmaceuticals Inc (ABOS)
Acumen Pharmaceuticals Inc market cap. Acumen Pharmaceuticals Inc (NASDAQ:ABOS) has a market capitalization of $16.93 Million ($16.93 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25477 globally and #5387 in its home market, demonstrating a -89.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Acumen Pharmaceuticals Inc's stock price $0.23 by its total outstanding shares 72227580 (72.23 Million). Also see Acumen Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Acumen Pharmaceuticals Inc Market Cap History (2021–2026)
Acumen Pharmaceuticals Inc market cap history from 2021 to 2026. Data shows change from $488.26 Million to $16.93 Million (-56.52% CAGR). Check ABOS stock price and chart for real-time trading data and today's change.
Index Memberships
Acumen Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #708 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2332 of 3165 |
Weight: Acumen Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Acumen Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Acumen Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Acumen Pharmaceuticals Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
340.01x
Acumen Pharmaceuticals Inc's market cap is 340.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $488.26 Million | $1.44 Million | -$100.61 Million | 340.01x | N/A |
Competitor Companies of ABOS by Market Capitalization
Companies near Acumen Pharmaceuticals Inc in the global market cap rankings as of November 4, 2026. Also see Acumen Pharmaceuticals Inc assets under control for a full breakdown of the balance sheet.
Key companies related to Acumen Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Acumen Pharmaceuticals Inc (2021–2026)
Market capitalization of Acumen Pharmaceuticals Inc from 2021 to today. Between 2021 and today, Acumen Pharmaceuticals Inc's market cap moved from $488.26 Million to $ 16.93 Million, with a yearly change of -56.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.93 Million | -88.89% |
| 2025 | $152.40 Million | +22.67% |
| 2024 | $124.23 Million | -55.21% |
| 2023 | $277.35 Million | -28.89% |
| 2022 | $390.03 Million | -20.12% |
| 2021 | $488.26 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Acumen Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.93 Million USD |
| MoneyControl | $16.93 Million USD |
| MarketWatch | $16.93 Million USD |
| marketcap.company | $16.93 Million USD |
| Reuters | $16.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more